Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that in young men with post-finasteride syndrome, there are potential genetic risk factors associated with psychological and sexual dysfunctions, suggesting genetic screening may be beneficial before prescribing finasteride.

This erratum addresses the long-term effects of finasteride on prostate-specific antigen levels but reports no new research findings.

Some men experience persistent sexual, neurological, and psychological symptoms after stopping finasteride, but evidence of permanent damage is inconclusive.

This study found that neutral liposomes were most effective at delivering minoxidil into pilosebaceous units compared to other tested formulations.

This case report describes a 26-year-old man who experienced persistent sexual dysfunction and other symptoms for 19 months after stopping finasteride for androgenetic alopecia. The authors highlight post-finasteride syndrome's impact on quality of life and stress the need for careful risk-benefit assessment before prescribing.

This study found significant differences in gene expression, particularly in androgen receptor activity, between men with post-finasteride syndrome and healthy controls, suggesting a potential biological basis for the syndrome.

This research emphasizes the importance of integrating pre-treatment psychological assessments for individuals considering finasteride, highlighting that these assessments could help identify those prone to nocebo responses, potentially reducing adverse symptom development more related to cognitive vulnerabilities than to the drug itself.

The authors concluded that finasteride and dutasteride might have serious side effects, including persistent sexual dysfunction for some, necessitating further research and vigilant risk-benefit analysis.

This article summarizes Dr. Alan Jacobs's presentation at the 2016 ISHRS World Congress but reports no new research findings.

The authors concluded that the concept of postfinasteride syndrome remains contentious and may be more plausibly characterized as a psychiatric condition rather than a consistent medical syndrome.

This case report describes an atypical postfinasteride syndrome in a patient treated with both dutasteride and finasteride for androgenic alopecia, highlighting its multisystem involvement and irreversible nature.

This study reported a significant increase in the reporting of sexual dysfunction associated with finasteride use, especially in individuals aged 31-45.

This review discusses post-finasteride syndrome, characterized by persistent symptoms despite discontinuation, and concludes that its existence cannot be confirmed; individualized assessment is advisable for those with a history of depression, sexual dysfunction, or infertility.

This study examined data from the FDA Adverse Event Reporting System and found that finasteride use is linked with both known and previously unlisted adverse events, such as erectile dysfunction and post-5α reductase inhibitor syndrome, with variations observed by age and sex.

This research overview discusses Post-Finasteride Syndrome, presenting data from an FDA database, but it does not report any new clinical findings.

This review discusses post-SSRI sexual dysfunction and post-finasteride syndrome, highlighting unknowns about their true incidence and underlying causes, and reports no new clinical results.

This report from the UK reviews the literature on post-menopausal frontal fibrosing alopecia and highlights its under-recognition and distinctive characteristics compared to lichen planopilaris, but does not provide new results.

In this study, researchers found no evidence of hemodynamic alterations associated with erectile dysfunction in men self-diagnosed with post-finasteride syndrome following the use of finasteride for hair loss.

This case study reports on a 44-year-old male exhibiting persistent neuropsychiatric symptoms described as Post-Finasteride Syndrome after discontinuing long-term finasteride use, highlighting the ongoing debate regarding its classification as a true disease process.

Finasteride for hair loss may cause long-lasting sexual side effects in young males.

This study found that women with PCOS have higher total PSA levels than controls, and the total PSA level correlates positively with testosterone and free androgen index.

This study suggests that paeoniflorin's protective effects on brain astrocytes may be mediated by TSPO and neurosteroids biosynthesis.

This study examines how conditions like PSSD, Long COVID, and ME/CFS form a "Post-Exposure Syndromes" family, initiated by transient exposures but persisting due to complex state-space dynamics, and suggests improving pharmacovigilance to better address and understand these persistent syndromes.

This study aimed to identify characteristics of patients who fail to void during pressure-flow studies, which limits the determination of the cause behind their lower urinary tract symptoms.

In this report, the European Medicines Agency confirmed in 2025 that finasteride, a drug used to treat hair loss in men, is linked to suicidal thoughts, a concern previously raised by patient advocacy groups.

This randomized pilot study suggests that finasteride may benefit some men with category IIIA chronic pelvic pain syndrome, although it is not recommended as monotherapy unless benign prostatic hyperplasia is also present.

This review discusses FAERS data on 5-alpha reductase inhibitors and their potential implications for post-finasteride syndrome, but it does not report any new clinical results.

The researchers reported that the facial Psoriasis Log-based Area and Severity Index (fPLASI) more reliably and sensitively captured clinical improvement in facial psoriasis than the existing facial Psoriasis Area and Severity Index (fPASI).

This study found that finasteride use is associated with both known and new adverse events, which vary by gender and age, as well as some events not previously listed in the drug insert.